Crimson Publishers Publish With Us Reprints e-Books Video articles

Abstract

Techniques in Neurosurgery & Neurology

Expression of Isocitrate Dehydrogenase-1 (IDH-1) Mutant Protein in Gliomas

  • Open or Close Jaiswal S1*, Chaudhary N1, Prasad P1, Khatri D2, Das KK2, Mehrotra A2, Jaiswal AK2, Pal L1 and Behari S2

    1Department of Pathology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, India

    2Department of Neurosurgery, Sanjay Gandhi Postgraduate Institute of Medical Sciences, India

    *Corresponding author: Sushila Jaiswal, MD, Additional Professor, Department of Pathology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Rae Bareli Road, Lucknow 226014 UP, India, Fax: 91-522-2668078, 2668017; Tel: 91-522-2495240; +918004904563; Email: sushilapath@yahoo.com

Submission: February 21, 2018; Published: March 09, 2018

DOI: 10.31031/TNN.2018.01.000514

ISSN 2637-7748
Volume1 Issue3

Abstract

Background and aim: Isocitrate dehydrogenase-1 (IDH-1) mutation in glioma has diagnostic and prognostic significance. The aim of this study was to determine the IDH-1 mutation in glioma and their correlation with various clinical parameters.

Material and methods: One hundred cases of glioma were studied for IDH-1 expression by immunohistochemistry (IHC).

Results: IDH-1 mutation was expressed in 36% (5/14) of children (age <16 years) and 53% (46/86) of adults (age >16 years). History of seizure was significantly associated with IDH-1 expression. Frontal location of tumor and absence of contrast enhancement were significantly associated with IDH-1 expression (P=0.23 and 0.001 respectively). IDH-1 positivity was noted in 47% (29/62) astrocytic tumors, 100% (3/3) oligoastrocytic tumors, 79% (15/19) oligodendroglial tumors and 25% (4/16) ependymal tumors. Overall, IDH-1 mutation was positive in 51% (51/100) of gliomas. IDH-1 expression was significantly higher in WHO grade II and grade III glioma (67% each) as compared to WHO grade IV and I (35% and 27% respectively).

Conclusion: IDH-1 mutation occurs in overall 51% of glioma. History of seizure, frontal location and absence of contrast enhancement on radiology are significantly associated with IDH-1 expression. IDH-1 is expressed mostly in oligoastrocytic tumors followed by oligodendroglial tumors, astrocytic tumors and least expressed in ependymal tumors. WHO grade II and III gliomas are more common to have IDH-1 expression than grade IV and grade I tumors.

Keywords: IDH-1 mutation; Glioma; Immunohistochemistry; Astrocytic tumors

Abbreviations: IDH-1: Isocitrate Dehydrogenase-1; IHC: Immunohistochemistry; ICP: Intracranial Pressure; CNS: Central Nervous System; WHO: World Health Organization; MGMT O6-Methylguanine-DNA MethylTransferase; EGFR: Epidermal Growth Factor Receptor; TCA: Tricarboxylic Acid; PCR: Polymerase Chain Reaction

Get access to the full text of this article